文献速递脑血管病外科神经重症

立体定向放射外科治疗出血性动静脉畸形的疗效:伴或不伴先前切除或栓塞

Outcomes of stereotactic radiosurgery for hemorrhagic arteriovenous malformations with or without prior resection or embolization.
PubMed 文献 · J Neurosurg · 2020-12-04

本研究分析410例接受立体定向放射外科(SRS)治疗的出血性动静脉畸形(rAVM)患者,比较单独SRS与手术或栓塞后SRS的疗效。结果显示手术+SRS组闭塞率高于单独SRS组(5年累积97% vs 79%,p<0.001),单独SRS组SRS后5年内年出血率1.5%、之后0.2%,10年无显著神经事件率95%。

要点

  • 手术+SRS组5年闭塞率97%,高于单独SRS组79%(p<0.001)。
  • 单独SRS组SRS后5年内年出血率1.5%,5年后0.2%。
  • 单独SRS组10年无显著神经事件率为95%。

核心结论

  • 单独SRS对出血性AVM有效,SRS后出血风险低。
  • SRS可用于初始干预后的残留AVM,尤其是切除失败后。

研究设计与样本

  • 回顾性分析410例连续接受SRS治疗的rAVM患者。
  • 按先前干预分为单独SRS组、手术+SRS组和栓塞+SRS组。
  • 比较单独SRS组与其他两组的结果,并进行倾向评分匹配分析。

主要发现

  • 手术+SRS组5年累积闭塞率97%,单独SRS组79%(p<0.001)。
  • 栓塞+SRS组与单独SRS组闭塞率无显著差异。
  • 多因素Cox分析显示先前切除(HR 1.78,95%CI 1.30-2.43,p<0.001)、最大AVM直径≤20 mm(HR 1.81,95%CI 1.43-2.30,p<0.001)和处方剂量≥20 Gy(HR 2.04,95%CI 1.28-3.27,p=0.003)与更好的闭塞率相关。
  • 单独SRS组SRS后5年内年出血率1.5%,之后0.2%;10年无显著神经事件率95%。
  • 多因素分析显示单独SRS不是SRS后出血或显著神经事件的危险因素。

关键数值与推荐

  • 手术+SRS组5年累积闭塞率97% vs 单独SRS组79%(p<0.001)。
  • 先前切除HR 1.78(95%CI 1.30-2.43,p<0.001)。
  • 最大AVM直径≤20 mm HR 1.81(95%CI 1.43-2.30,p<0.001)。
  • 处方剂量≥20 Gy HR 2.04(95%CI 1.28-3.27,p=0.003)。
  • 单独SRS组SRS后5年内年出血率1.5%,之后0.2%;10年无显著神经事件率95%。

临床怎么用

  • rAVM治疗策略应个体化,综合考虑相关因素。
  • 单独SRS可作为出血性AVM的有效治疗选择。
  • SRS可用于初始干预后的残留AVM,尤其是切除失败后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The major concern about ruptured arteriovenous malformations (rAVMs) is recurrent hemorrhage, which tends to preclude stereotactic radiosurgery (SRS) as a therapeutic modality for these brain malformations. In this study, the authors aimed to clarify the role of SRS for rAVM as a stand-alone modality and an adjunct for a remnant nidus after surgery or embolization. METHODS: Data on 410 consecutive patients with rAVMs treated with SRS were analyzed. The patients were classified into groups, according to prior interventions: SRS-alone, surgery and SRS (Surg-SRS), and embolization and SRS (Embol-SRS) groups. The outcomes of the SRS-alone group were analyzed in comparison with those of the other two groups. RESULTS: The obliteration rate was higher in the Surg-SRS group than in the SRS-alone group (5-year cumulative rate 97% vs 79%, p < 0.001), whereas no significant difference was observed between the Embol-SRS and SRS-alone groups. Prior resection (HR 1.78, 95% CI 1.30-2.43, p < 0.001), a maximum AVM diameter ≤ 20 mm (HR 1.81, 95% CI 1.43-2.30, p < 0.001), and a prescription dose ≥ 20 Gy (HR 2.04, 95% CI 1.28-3.27, p = 0.003) were associated with a better obliteration rate, as demonstrated by multivariate Cox proportional hazards analyses. In the SRS-alone group, the annual post-SRS hemorrhage rates were 1.5% within 5 years and 0.2% thereafter and the 10-year significant neurological event-free rate was 95%; no intergroup difference was observed in either outcome. The exclusive performance of SRS (SRS alone) was not a risk for post-SRS hemorrhage or for significant neurological events based on multivariate analyses. These results were also confirmed with propensity score-matched analyses. CONCLUSIONS: The treatment strategy for rAVMs should be tailored with due consideration of multiple factors associated with the patients. Stand-alone SRS is effective for hemorrhagic AVMs, and the risk of post-SRS hemorrhage was low. SRS can also be favorably used for residual AVMs after initial interventions, especially after failed resection.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Kawashima M, Hasegawa H, Shin M, et al. Outcomes of stereotactic radiosurgery for hemorrhagic arteriovenous malformations with or without prior resection or embolization. J Neurosurg. 2020. PMID: 33276336. doi:10.3171/2020.7.JNS201502

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。